Cognition Therapeutics, Inc.
CGTXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jun 22, 2026 | H.C. Wainwright | Raghuram Selvaraju | $3.00(+107%) | $1.45 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Chardan Capital | maintain | Buy | Mar 27, 2026 |
| HC Wainwright & Co. | maintain | Buy | Dec 4, 2025 |
| B. Riley Securities | maintain | Buy | Nov 21, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 19, 2025 |
| Chardan Capital | maintain | Buy | Aug 8, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jun 26, 2025 |
| HC Wainwright & Co. | maintain | Buy | May 27, 2025 |
| Chardan Capital | maintain | Buy | May 8, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 24, 2025 |
| Chardan Capital | maintain | Buy | Mar 21, 2025 |
| Chardan Capital | maintain | Buy | Feb 26, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 19, 2024 |
| B. Riley Securities | upgrade | Neutral →Buy | Dec 19, 2024 |
| Chardan Capital | maintain | Buy | Dec 19, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 27, 2024 |
| Chardan Capital | maintain | Buy | Nov 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 4, 2024 |
| Chardan Capital | maintain | Buy | Oct 31, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 12, 2024 |
| B. Riley Securities | downgrade | Buy →Neutral | Aug 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 1, 2024 |
| Cantor Fitzgerald | downgrade | Overweight →Neutral | Jul 30, 2024 |
| Rodman & Renshaw | maintain | Buy | Jul 2, 2024 |
| B. Riley Securities | maintain | Buy | Mar 28, 2024 |
| Oppenheimer | maintain | Outperform | Mar 27, 2024 |
Earnings History
Next report: Mar 25, 2027 · EPS est. $-0.14| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-0.04 | $-0.07 | — | $5.3M |
| Aug 6, 2026 | $-0.04 | $-0.06 | — | $5.0M |
| May 7, 2026 | $-0.05 | $-0.06 | — | $4.4M |
| Mar 26, 2026 | $-0.02 | $-0.06 | — | — |
| Nov 6, 2025 | $-0.06 | $-0.07 | — | — |
| Aug 7, 2025 | $-0.11 | $-0.12 | — | — |
| May 7, 2025 | $-0.14 | $-0.12 | — | — |
| Mar 20, 2025 | $-0.17 | $-0.16 | — | — |
News
Cognition Therapeutics, Inc. (CGTX) Q3 2026 Earnings Call Transcript
Cognition Therapeutics NASDAQ: CGTX is preparing a Phase III trial of its experimental drug zervimesine in dementia with Lewy bodies after reaching alignment with the U.S. Food and Drug Administration on a planned registrational study, executives said on the company's third-quarter 2026 earnings call.
PURCHASE, N.Y., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results for the third quarter ended September 30, 2026, and provided a business update.
-- Conference Call and Webcast 8:30 a.m. ET November 5 -- PURCHASE, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today announced that the Company will host a conference call and webcast on November 5, 2026, at 8:30 a.m. Eastern Time to report its financial results for the third quarter ended September 30, 2026, and provide a busines…
PURCHASE, N.Y., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, has aligned with the U.S. Food and Drug Administration (FDA) on key elements of a Phase 3 study in dementia with Lewy bodies (DLB) including patient selection, dose, duration, and endpoints.
- An additional five years of patent protection may be possible through a standard extension - - An additional five years of patent protection may be possible through a standard extension -
October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3 October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3
PURCHASE, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi intends to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 2:30 p.m. Eastern Time. During her presentation, Ms. Ricciardi will discuss progress on the Company's development of zervimesine for Alzheimer…